Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

NCT: NCT03502785 · COMPLETED

NCT IDNCT03502785
StatusCOMPLETED
Start Date2018-07-24
Completion2025-05-09
SponsorInovio Pharmaceuticals (INDUSTRY)
First posted
Last updated

Brief Summary

This was a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population was divided into two cohorts: Cohort A: participants with locally advanced unresectable or metastatic/recurrent UCa, who had confirmed disease progression during or following treatment with anti-programmed death receptor-1/programmed death receptor ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: participants with locally advanced unresectable or metastatic/recurrent UCa, who were treatment naïve and ineligible for cisplatin-based chemotherapy. A safety run-in was performed using a modified rolling six design, enrolling up to 6 participants (safety analysis participants) from Cohort A.

Frequently Asked Questions

What is INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma?

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma is a clinical trial registered under NCT03502785. Current status: COMPLETED.

What is the status of NCT03502785?

The current status of NCT03502785 (INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma) is: COMPLETED.

When did INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma start?

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma started on 2018-07-24.

Related Devices

PMA P150013Immunohistochemistry assay, antibody, programmed death-ligand 1Agilent Technologies, Inc. PMA P150025Immunohistochemistry assay, antibody, programmed death-ligand 1Agilent Technologies, Inc. PMA P150027Immunohistochemistry assay, antibody, programmed death-ligand 1Dako North America, Inc. PMA P160002Immunohistochemistry assay, antibody, programmed death-ligand 1Ventana Medical Systems, Inc. PMA P160006Immunohistochemistry assay, antibody, programmed death-ligand 1Ventana Medical Systems, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑